文献速递帕金森病与运动障碍认知障碍与痴呆

特发性快速眼动睡眠行为障碍的尸检神经病理学:病例系列

Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series.
PubMed 文献 · Lancet Neurol · 2024-01-01

该病例系列在西班牙巴塞罗那医院诊所分析了20例经视频多导睡眠图诊断的特发性快速眼动睡眠行为障碍(IRBD)患者的尸检脑和脊髓组织,其中19例(95%)为路易体病,1例(5%)为多系统萎缩(MSA)。所有参与者均在调节快速眼动睡眠肌张力的结构中存在α-突触核蛋白沉积,且所有参与者均存在共病病理。作者认为IRBD是α-突触核蛋白相关神经退行性疾病的早期阶段。

要点

  • 20例IRBD患者尸检中,路易体病19例(95%),MSA 1例(5%)。
  • 所有参与者均存在调节快速眼动睡眠肌张力的结构中的α-突触核蛋白沉积。
  • 所有参与者均存在共病病理,以阿尔茨海默病病理最为常见(14例,70%)。

核心结论

  • 尽管受相对较小的样本量限制,观察结果提供了强有力的神经病理学证据,表明IRBD是α-突触核蛋白相关神经退行性疾病的早期阶段。
  • 共病病理常见,其作用仍有待阐明:一些可能促进了痴呆的发生,而另一些可能是年龄相关改变。
  • 研究结果可为针对IRBD患者特定病理蛋白(如α-突触核蛋白和淀粉样β)的临床试验设计提供信息。

研究设计与样本

  • 本研究为病例系列,在西班牙巴塞罗那的巴塞罗那医院诊所进行。
  • 研究对象为2005年5月28日至2023年3月23日期间成为神经组织库捐赠者的、经视频多导睡眠图诊断为IRBD的个体。
  • 检查了20例IRBD个体的尸检脑组织和脊髓,使用针对α-突触核蛋白、淀粉样β、磷酸化tau、三重复和四重复tau亚型以及TDP-43的抗体评估神经元丢失、胶质增生和蛋白聚集的存在与分布。
  • 由于样本量小,未进行对比统计分析,但描述了各核团和脑结构间观察到的差异。

主要发现

  • 共检查20例IRBD个体的脑和脊髓,其中男性19例(95%),女性1例(5%)。
  • 临床生前诊断:无其他神经系统疾病的IRBD 3例(15%),无痴呆的帕金森病2例(10%),帕金森病痴呆(PDD)3例(15%),路易体痴呆(DLB)12例(60%)。
  • 尸检神经病理学诊断:路易体病19例(95%),多系统萎缩(MSA)1例(5%)。
  • 所有路易体病和MSA参与者均显示神经元丢失、胶质增生以及神经元和星形胶质细胞中的α-突触核蛋白沉积;所有参与者的α-突触核蛋白均存在于调节快速眼动睡眠肌张力的结构中(如亚蓝斑核、巨细胞网状核、背外侧被盖和杏仁核)。
  • 所有参与者均存在共病病理:阿尔茨海默病病理(淀粉样β斑块和神经原纤维缠结)14例(70%),年龄相关tau星形胶质细胞病12例(60%),脑淀粉样血管病11例(55%),嗜银颗粒病4例(20%),边缘系统为主年龄相关TDP-43脑病4例(20%),提示进行性核上性麻痹的早期改变3例(15%)。

局限性

  • 样本量相对较小。
  • 共病病理的作用仍有待阐明。
  • 研究结果可为针对IRBD患者特定病理蛋白(如α-突触核蛋白和淀粉样β)的临床试验设计提供信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Idiopathic rapid eye movement (REM) sleep behaviour disorder (IRBD) is thought to be an early stage of α-synuclein-related neurodegenerative diseases. Nevertheless, the definitive identification of its biological substrate can be determined only by post-mortem neuropathology. We aimed to describe the post-mortem neuropathology of individuals with IRBD who developed or did not develop a neurodegenerative disease before death. METHODS: In this case series at the Hospital Clinic de Barcelona, Barcelona, Spain, we examined post-mortem brain tissue and spinal cords from individuals diagnosed with IRBD by video polysomnography who became donors to the Neurological Tissue Bank between May 28, 2005, and March 23, 2023. We performed post-mortem neuropathology to assess the presence and distribution of neuronal loss, gliosis, and protein aggregates using antibodies against α-synuclein, amyloid β, phosphorylated tau, three-repeat and four-repeat tau isoforms, and TDP-43. Comparative statistical analyses were not done because of the small sample size, but differences observed across the nuclei and brain structures were described. FINDINGS: The brains and spinal cords of 20 individuals with IRBD were examined (19 [95%] men, one [5%] woman). Their clinical antemortem diagnoses were of IRBD without any other neurological disorder in three (15%), Parkinson's disease without dementia in two (10%), Parkinson's disease dementia (PDD) in three (15%), and dementia with Lewy bodies (DLB) in 12 (60%) individuals. Post-mortem neuropathological diagnoses were Lewy body disease in 19 (95%) and multiple system atrophy (MSA) in one (5%). All participants with Lewy body disease and MSA showed neuronal loss, gliosis, and α-synuclein deposits in neurons and astrocytes. In all participants, α-synuclein was found in the structures that regulate REM sleep atonia (eg, subcoeruleus nucleus, gigantocellular reticular nucleus, laterodorsal tegmentum, and amygdala). Coexistent pathologies were found in all participants, including Alzheimer's disease pathology (amyloid β plaques and neurofibrillary tangles) in 14 (70%), ageing-related tau astrogliopathy in 12 (60%), cerebral amyloid angiopathy in 11 (55%), argyrophilic grain disease in four (20%), limbic-predominant age-related TDP-43 encephalopathy in four (20%), and early changes indicative of progressive supranuclear palsy in three (15%). In individuals with IRBD without any other neurological disorder and in those who developed Parkinson's disease without dementia, α-synuclein was found in the brainstem and limbic system and rarely in the cortex, whereas coexisting proteinopathies were few and showed mild pathological burden. In contrast, in individuals who developed PDD or DLB, α-synuclein had diffuse distribution in the brainstem, limbic system, and cortex, and multiple comorbid pathologies were common, particularly those related to Alzheimer's disease. INTERPRETATION: Although limited by a relatively small sample size, our observations provide strong neuropathological evidence that IRBD is an early stage of α-synuclein-related neurodegenerative disease. Concomitant pathologies are frequent and their role remains to be clarified: some might have contributed to the development of dementia, but some might be age-related changes. Our findings could inform the design of clinical trials of compounds that target specific pathological proteins (eg, α-synuclein and amyloid β) in people with IRBD. FUNDING: Fundación BBVA-Hospital Clínic de Barcelona.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Mayà G, Iranzo A, Gaig C, et al. Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series. Lancet Neurol. 2024. PMID: 39577924. doi:10.1016/S1474-4422(24)00402-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。